Testing HS-20122 combined therapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This early-stage trial tests a new drug combination (HS-20122) for non-small cell lung cancer that has spread or cannot be surgically removed. You may qualify if your cancer has progressed despite prior treatment or you haven't received prior treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or spread non-small cell lung cancer (NSCLC)
- You've had at least one prior cancer treatment, or you're treatment-naive (haven't received prior treatment)
- Your cancer has at least one measurable tumor on imaging
- Your overall health and organ function are adequate
- You're active enough to perform light activities (ECOG score 0–1)
- You expect to live at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that has a specific gene change (EGFR mutation or MET-positive) and has worsened after prior treatment. It aims to see if the combination is safe and effective.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new drug, HRS-4508, given with other cancer treatments for people with advanced non-small cell lung cancer whose previous treatments have failed. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
This trial tests a new drug called HS-20122 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.